Government-Owned Inventions; Availability for Licensing, 70690-70691 [2016-24693]

Download as PDF 70690 Federal Register / Vol. 81, No. 198 / Thursday, October 13, 2016 / Notices Lhorne on DSK30JT082PROD with NOTICES Closed: April 6, 2017, 12:00 p.m. to 4:30 p.m. Agenda: To review and evaluate personal qualifications, performance, and competence of individual investigators. Place: National Library of Medicine, Building 38, 2nd Floor, The Lindberg Room, 8600 Rockville Pike, Bethesda, MD 20892. Closed: April 7, 2017, 9:00 a.m. to 10:00 a.m. Agenda: To review and evaluate personal qualifications, performance, and competence of individual investigators. Place: National Library of Medicine, Building 38, 2nd Floor, The Lindberg Room, 8600 Rockville Pike, Bethesda, MD 20892. Contact Person: Karen Steely, Program Assistant, Lister Hill National Center for Biomedical Communications, National Library of Medicine, Building 38A, Room 7S707, Bethesda, MD 20892, 301–827–4385, ksteely@mail.nih.gov. Open: April 7, 2017, 10:00 a.m. to 11:30 a.m. Agenda: Review of research and development programs and preparation of reports of the Lister Hill National Center for Biomedical Communications. Place: National Library of Medicine, Building 38, 2nd Floor, The Lindberg Room, 8600 Rockville Pike, Bethesda, MD 20892. Contact Person: Karen Steely, Program Assistant, Lister Hill National Center for Biomedical Communications, National Library of Medicine, Building 38A, Room 7S707, Bethesda, MD 20892, 301–827–4385, ksteely@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. (Catalogue of Federal Domestic Assistance Program No. 93.879, Medical Library Assistance, National Institutes of Health, HHS) DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Human Tissue Models For Infectious Diseases (U19). Date: November 16, 2016. Time: 11:00 a.m. to 2:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Brenda Lange-Gustafson, Ph.D., Scientific Review Officer, NIAID/NIH/ DHHS, Scientific Review Program, 5601 Fishers Lane, Room 3G13, Rockville, MD 20852, 240–669–5047, bgustafson@ niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: October 6, 2016. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–24686 Filed 10–12–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Dated: October 5, 2016. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. Government-Owned Inventions; Availability for Licensing [FR Doc. 2016–24705 Filed 10–12–16; 8:45 am] HHS. BILLING CODE 4140–01–P ACTION: AGENCY: National Institutes of Health, Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for SUMMARY: VerDate Sep<11>2014 14:07 Oct 12, 2016 Jkt 241001 PO 00000 Frm 00027 Fmt 4703 Sfmt 4703 licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the National Heart, Lung and Blood Institute, Office of Technology Transfer and Development, National Institutes of Health, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892–2479; telephone: 301–402–5579. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications. SUPPLEMENTARY INFORMATION: Technology descriptions follow. Enhanced Functionalization of Carbon Nanoparticles for Biomedical Applications Description of Technology The invention pertains to methods of increasing the density of carboxylic acids on the surface of a carbon nanoparticle that can be functionalized with biologically relevant molecules, such as antibodies or peptides, for biomedical applications. Advantageously, the method could increase functionalization of a nanoparticle by at least about 1x107 functional groups/g of nanoparticle. The method includes contacting an oxygencontaining functional group on a surface of a carbon nanoparticle with a reducing agent to provide a hydroxyl group; reacting the hydroxyl group with a diazoacetate ester in the presence of a transition metal catalyst to provide an ester and then cleaving the ester to provide a carboxylic acid group. The carboxylic acid can further be secondarily functionalized to an acyl chloride, an amide, pegylated, a biotinylate, a folate, a thiol, a maleimide, an active ester, an amine, a chelated gadolinium, an azide, an alkyne, a protein tag, or a dendrimer. Examples of notable nanoparticles that can be derivatized using this method include carbon nanoparticles such as carbon nanotubes, fullerenes, graphenes, graphene oxides, and nanodiamonds; with or without fluorescent properties. Fluorescent nanoparticles are of particular interest for functionalization as they are applicable to both research and E:\FR\FM\13OCN1.SGM 13OCN1 Federal Register / Vol. 81, No. 198 / Thursday, October 13, 2016 / Notices diagnostic applications and can be visualized through microscopy. Potential Commercial Applications • Imaging • Therapeutics Competitive Advantages • Higher degree of functionalization for carbon nanoparticles Development Stage • Early Stage Inventors: Keir Neuman, Rolf Swenson, Ganesh Shenoy, Chandrasekhar Mushti (all of NHLBI). Lhorne on DSK30JT082PROD with NOTICES Dated: October 6, 2016. Michael Shmilovich, National Heart, Lung and Blood Institute, Office of Technology Transfer and Development, National Institutes of Health. [FR Doc. 2016–24693 Filed 10–12–16; 8:45 am] BILLING CODE 4140–01–P Publications: 1. Mochalin, V. N.; Shenderova, O.; Ho, D.; Gogotsi, Y., The Properties and Applications of Nanodiamonds. Nature Nanotechnology 2012, 7 (1), 11–23. 2. Huang, J.; Deming, C. P.; Song, Y.; Kang, X.; Zhou, Z.-Y.; Chen, S., Chemical Analysis of Surface Oxygenated Moieties of Fluorescent Carbon Nanoparticles. Nanoscale 2012, 4 (3), 1010–1015. 3. Nystrom, R. F.; Brown, W. G., Reduction of Organic Compounds by Lithium Aluminum Hydride. I. Aldehydes, Ketones, Esters, Acid Chlorides and Acid Anhydrides. Journal of the American Chemical Society 1947, 69 (5), 1197– 1199. 4. Nystrom, R. F.; Brown, W. G., Reduction of Organic Compounds by Lithium Aluminum Hydride. Ii. Carboxylic Acids. Journal of the American Chemical Society 1947, 69 (10), 2548–2549. 5. Aller, E.; Brown, D. S.; Cox, G. G.; Miller, D. J.; Moody, C. J. Diastereoselectivity in the O–H Insertion Reactions of Rhodium Carbenoids Derived from Phenyldiazoacetates of Chiral Alcohols. Preparation Of .Alpha.-Hydroxy And .Alpha.-Alkoxy Esters. The Journal of Organic Chemistry 1995, 60 (14), 4449– 4460. 6. Hoehnel, S; Lutolf, M.P., Capturing CellCell Interactions via SNAP-tag and CLIPtag Techology. Bioconjugate Chemistry 2015, 26, 1678–1686. 7. Moon, W. K.; Lin, Y.; O’Loughlin, T.; Tang, Y.; Kim, D.-E.; Weissleder, R.; and Tung, C.-H., Enhanced Tumor Detection Using a Folate Receptor-Targeted Near-Infrared Fluorochrome Conjugate. Bioconjugate Chemistry 2003, 14, 539–545. 8. Fu, C. C.,Lee, H. Y., Chen, K. C., Lim, T. S.,Wu, H. Y., Lin, P. K.,Wei, P. K., Tsao, P. H., Chang, H. C., Fann, W. Characterization and application of single fluorescent nanodiamonds as cellular biomarkers. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104(3), 727–732. 9. Chang, B. M., Lin, H. H., Su, L. J., Lin, W. D., Lin, R. J., Tzeng, Y. K, Lee, R. T., Lee, Y. C., Yu, A. L., Chang, H. C., Highly Fluorescent Nanodiamonds ProteinFunctionalized for Cell Labeling and Targeting. Advanced Functional Materials 23(46): 5737–5745. VerDate Sep<11>2014 Intellectual Property: HHS Reference No. E–207–2016/0. • US Provisional Patent Application No. 62/402,339 filed 30 September 2016. Licensing Contact: Michael Shmilovich, Esq, CLP; 301–435–5019; shmilovm@mail.nih.gov. 14:07 Oct 12, 2016 Jkt 241001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Heart, Lung, and Blood Initial Review Group; NHLBI Mentored Transition to Independence Review Committee. Date: November 3–4, 2016. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: The William F. Bolger Center, 9600 Newbridge Drive, Potomac, MD 20854. Contact Person: Giuseppe Pintucci, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 7192, Bethesda, MD 20892, 301–435–0287, Pintuccig@nhlbi.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 70691 October 5, 2016. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2016–24694 Filed 10–12–16; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Notice of Diabetes Mellitus Interagency Coordinating Committee meeting The Diabetes Mellitus Interagency Coordinating Committee (DMICC) will hold a meeting on October 18, 2016. The subject of the meeting will be ‘‘How Reproducible Are People? Understanding Health Histories Using Medicare Claims Data.’’ The meeting is open to the public. DATES: The meeting will be held on October 18, 2016; from 1:00 p.m. to 3:30 p.m. Individuals wanting to present oral comments must notify the contact person at least 10 days before the meeting date. ADDRESSES: The meeting will be held in the Democracy 2 Building at 6707 Democracy Blvd., Bethesda, MD, in Conference Room 7050. FOR FURTHER INFORMATION CONTACT: For further information concerning this meeting, see the DMICC Web site, www.diabetescommittee.gov, or contact Dr. B. Tibor Roberts, Executive Secretary of the Diabetes Mellitus Interagency Coordinating Committee, National Institute of Diabetes and Digestive and Kidney Diseases, 31 Center Drive, Building 31A, Room 9A19, MSC 2560, Bethesda, MD 20892– 2560, telephone: 301–496–6623; FAX: 301–480–6741; email: dmicc@ mail.nih.gov. SUPPLEMENTARY INFORMATION: The DMICC, chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) comprising members of the Department of Health and Human Services and other federal agencies that support diabetes-related activities, facilitates cooperation, communication, and collaboration on diabetes among government entities. DMICC meetings, held several times a year, provide an opportunity for Committee members to learn about and discuss current and future diabetes programs in DMICC member organizations and to identify opportunities for collaboration. The October 18, 2016 DMICC meeting will focus on How Reproducible Are People? Understanding Health Histories Using Medicare Claims Data. SUMMARY: E:\FR\FM\13OCN1.SGM 13OCN1

Agencies

[Federal Register Volume 81, Number 198 (Thursday, October 13, 2016)]
[Notices]
[Pages 70690-70691]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-24693]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious 
commercialization of federally-funded research and development. Foreign 
patent applications are filed on selected inventions to extend market 
coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent applications listed below may be obtained by writing to 
the indicated licensing contact at the National Heart, Lung and Blood 
Institute, Office of Technology Transfer and Development, National 
Institutes of Health, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 
20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure 
Agreement may be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follow.

Enhanced Functionalization of Carbon Nanoparticles for Biomedical 
Applications

Description of Technology

    The invention pertains to methods of increasing the density of 
carboxylic acids on the surface of a carbon nanoparticle that can be 
functionalized with biologically relevant molecules, such as antibodies 
or peptides, for biomedical applications. Advantageously, the method 
could increase functionalization of a nanoparticle by at least about 
1x10\7\ functional groups/g of nanoparticle. The method includes 
contacting an oxygen-containing functional group on a surface of a 
carbon nanoparticle with a reducing agent to provide a hydroxyl group; 
reacting the hydroxyl group with a diazoacetate ester in the presence 
of a transition metal catalyst to provide an ester and then cleaving 
the ester to provide a carboxylic acid group. The carboxylic acid can 
further be secondarily functionalized to an acyl chloride, an amide, 
pegylated, a biotinylate, a folate, a thiol, a maleimide, an active 
ester, an amine, a chelated gadolinium, an azide, an alkyne, a protein 
tag, or a dendrimer. Examples of notable nanoparticles that can be 
derivatized using this method include carbon nanoparticles such as 
carbon nanotubes, fullerenes, graphenes, graphene oxides, and 
nanodiamonds; with or without fluorescent properties. Fluorescent 
nanoparticles are of particular interest for functionalization as they 
are applicable to both research and

[[Page 70691]]

diagnostic applications and can be visualized through microscopy.

Potential Commercial Applications

 Imaging
 Therapeutics

Competitive Advantages

 Higher degree of functionalization for carbon nanoparticles

Development Stage

 Early Stage

    Inventors: Keir Neuman, Rolf Swenson, Ganesh Shenoy, Chandrasekhar 
Mushti (all of NHLBI).

Publications:

1. Mochalin, V. N.; Shenderova, O.; Ho, D.; Gogotsi, Y., The 
Properties and Applications of Nanodiamonds. Nature Nanotechnology 
2012, 7 (1), 11-23.
2. Huang, J.; Deming, C. P.; Song, Y.; Kang, X.; Zhou, Z.-Y.; Chen, 
S., Chemical Analysis of Surface Oxygenated Moieties of Fluorescent 
Carbon Nanoparticles. Nanoscale 2012, 4 (3), 1010-1015.
3. Nystrom, R. F.; Brown, W. G., Reduction of Organic Compounds by 
Lithium Aluminum Hydride. I. Aldehydes, Ketones, Esters, Acid 
Chlorides and Acid Anhydrides. Journal of the American Chemical 
Society 1947, 69 (5), 1197-1199.
4. Nystrom, R. F.; Brown, W. G., Reduction of Organic Compounds by 
Lithium Aluminum Hydride. Ii. Carboxylic Acids. Journal of the 
American Chemical Society 1947, 69 (10), 2548-2549.
5. Aller, E.; Brown, D. S.; Cox, G. G.; Miller, D. J.; Moody, C. J. 
Diastereoselectivity in the O-H Insertion Reactions of Rhodium 
Carbenoids Derived from Phenyldiazoacetates of Chiral Alcohols. 
Preparation Of .Alpha.-Hydroxy And .Alpha.-Alkoxy Esters. The 
Journal of Organic Chemistry 1995, 60 (14), 4449-4460.
6. Hoehnel, S; Lutolf, M.P., Capturing Cell-Cell Interactions via 
SNAP-tag and CLIP-tag Techology. Bioconjugate Chemistry 2015, 26, 
1678-1686.
7. Moon, W. K.; Lin, Y.; O'Loughlin, T.; Tang, Y.; Kim, D.-E.; 
Weissleder, R.; and Tung, C.-H., Enhanced Tumor Detection Using a 
Folate Receptor-Targeted Near-Infrared Fluorochrome Conjugate. 
Bioconjugate Chemistry 2003, 14, 539-545.
8. Fu, C. C.,Lee, H. Y., Chen, K. C., Lim, T. S.,Wu, H. Y., Lin, P. 
K.,Wei, P. K., Tsao, P. H., Chang, H. C., Fann, W. Characterization 
and application of single fluorescent nanodiamonds as cellular 
biomarkers. Proceedings of the National Academy of Sciences of the 
United States of America, 2007, 104(3), 727-732.
9. Chang, B. M., Lin, H. H., Su, L. J., Lin, W. D., Lin, R. J., 
Tzeng, Y. K, Lee, R. T., Lee, Y. C., Yu, A. L., Chang, H. C., Highly 
Fluorescent Nanodiamonds Protein-Functionalized for Cell Labeling 
and Targeting. Advanced Functional Materials 23(46): 5737-5745.

    Intellectual Property: HHS Reference No. E-207-2016/0.
     US Provisional Patent Application No. 62/402,339 filed 30 
September 2016.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
shmilovm@mail.nih.gov.

    Dated: October 6, 2016.
Michael Shmilovich,
National Heart, Lung and Blood Institute, Office of Technology Transfer 
and Development, National Institutes of Health.
[FR Doc. 2016-24693 Filed 10-12-16; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.